Biomedical Engineer Salary Guide 2026

Last updated: May 15, 2026 | By Tom Kenaley

Biomedical engineers in the United States earn $82,200 to $175,970 in 2026 with a national median of $106,950, and the spread tracks specialization more than seniority. Medical device, imaging, and regulated R&D pay 20% to 35% above the average, while clinical engineer and field service roles sit closer to the floor. Most salary aggregators conflate these into a single number that makes the budget feel cleaner than it is. The cleaner read is by what the engineer actually owns when the FDA shows up.

Tom Kenaley, co-founder of KORE1. Twenty-plus years placing engineering and life sciences talent across Orange County, San Diego, the Bay Area, Boston, and Minneapolis, and a lot of that volume has run through medical device R&D, implantables, and SaMD teams that are now competing against each other for the same fifty senior engineers. Biomedical engineering has been one of our most consistently underpriced engineering categories for two years running, and the gap between aggregator numbers and actual offers has only widened since the medical device M&A wave in late 2025 reshuffled the senior-engineer market across Edwards, Boston Scientific, and the second-tier device buyers.

I will disclose the conflict up front. KORE1 places biomedical engineers through our biomedical engineering staffing practice and earns a fee when our clients hire through us. The numbers in this guide come from BLS, six public aggregators, and KORE1’s own placed-base data from Q3 2025 through Q1 2026. I will name where the public sources mislead, and where one phone call to a recruiter saves a six-week search.

What Six Salary Sources Report Biomedical Engineers Earn

No two aggregators define the role the same way. BLS bundles bioengineers and biomedical engineers under SOC 17-2031 — a tight occupational match that captures the regulated device and R&D population. Glassdoor pulls self-reported total pay, which leans senior. ZipRecruiter scrapes active listings, where junior and field service roles drag the median down. PayScale’s self-survey skews toward candidates suspicious they are underpaid. Same role title, six different population samples, and a $47,000 spread.

PayScale’s $81,907 is a soft floor, not a market read. The self-survey pulls from candidates who went searching because they suspected they were under-paid, which produces a sample that is structurally biased toward the low end of the actual market across most engineering disciplines we have benchmarked it against. ZipRecruiter’s $94,807 runs low because the active-listings pool oversamples clinical engineer and biomed tech postings that are often closer to medical instrumentation technician work than to the SOC 17-2031 regulated R&D population the title implies.

Glassdoor’s $129,492 leans high for a different reason. The self-reporters skew toward Bay Area, Boston, and Minneapolis device employers where principal and staff biomedical engineers post their total pay after the offer clears. That sample does not represent the median seat in a 40-person device startup outside of those metros.

KORE1’s placed-base sits in the middle by design. The $112,800 number reflects what midmarket device, biotech, and regulated R&D clients actually signed across 47 placements over two and a half quarters. It excludes equity. It excludes signing bonuses. The 25th-percentile floor of $89,000 captures associate-tier and early-career hires, mostly in San Diego, Salt Lake City, and Minneapolis. The 75th of $148,000 captures senior R&D engineers at Class II and Class III device firms in Irvine, the Bay Area, and the Route 128 corridor.

For the federal anchor, the Bureau of Labor Statistics reports 22,200 bioengineer and biomedical engineer jobs nationally in 2024, with employment projected to grow 5% from 2024 to 2034 — faster than the all-occupation average. About 1,300 openings annually. The 90th percentile clears $175,970, which lines up with senior medical device and imaging principal engineer placements on our side.

Biomedical Engineer Salary by Experience Level

Years in the seat matter, but not the way a generic “5 to 7 years” template suggests. A candidate with eight years in mechanical engineering and one year on a Class II device team is mid-level for our purposes, not senior. The expensive muscle is regulatory fluency. Design controls under 21 CFR 820. Risk management to ISO 14971. Verification and validation protocols that survive an FDA inspection. None of that develops sitting next to a non-regulated R&D bench.

Two patterns show up over and over in our placement data. First, the mid-to-senior jump is wider than most candidates expect — roughly $30,000 — and the bridge is exactly one thing, namely a cleared 510(k) submission, a verified design history file, or a verification protocol that survived an FDA inspection with the candidate’s name on it. Candidates who have shipped a device through regulatory get senior offers. Candidates who have been adjacent to one get mid offers with a director who will revisit in twelve months.

Second, the staff-to-principal line gets blurry inside startups. A 7-year engineer at a 30-person device startup running a single program will get a “principal” title and a $145,000 base. The same person at Medtronic with the same scope is a senior engineer at $140,000. The principal title at the startup is a retention play, not a comp upgrade. Read past the title.

Salary by Specialization — Where the $40,000 Spreads Show Up

The role splits into at least eight specializations that share an SOC code but almost nothing else. We have placed all of them in the past 18 months. The comp variance between specializations swamps the variance between mid and senior in the same specialization.

Software as a Medical Device is the sleeper category for 2026. The IEC 62304 fluency plus Python or embedded C plus regulatory chops is a three-skill stack that almost no candidate has at the senior tier, because the people who could build it five years ago either left for non-regulated software, took a director seat, or got pulled into AI/ML medical imaging where the comp is even higher and the regulatory burden is somebody else’s problem. We ran a SaMD senior search for a continuous glucose monitor company in Q1 that took 67 days because the cleared population at that intersection sits in the low hundreds nationally. The closing offer landed at $178,000 base plus equity. The original budget was $155,000.

Clinical biomed engineers — the hospital-employed population that services infusion pumps, ventilators, and patient monitors — get bundled into BLS aggregates and drag the median down. Different population, different work, different supply pipeline. We sometimes get a clinical biomed candidate applying to a device R&D req. Different career track. The conversion rate from clinical to R&D is under 8% from what we have tracked, mostly because the regulatory and design-controls muscle does not get built on the hospital floor.

Salary by State — Where the Money Is

Three states own the top of the biomedical engineering pay distribution. California, Massachusetts, and Minnesota together employ roughly 40% of the SOC 17-2031 population and pay 12% to 22% above the national median, with the spread driven mostly by the medical device industry concentration in each cluster and the corresponding willingness of Edwards, Medtronic, Boston Scientific, and the second-tier device firms to bid against each other for the same fifty cleared senior engineers in each market. Within California, the breakdown matters: Orange County (Irvine, Lake Forest, Aliso Viejo — Edwards Lifesciences, Glaukos, Masimo territory) runs slightly higher than San Diego, which runs higher than the Bay Area for the implantables and cardiovascular subspecialty. The Bay Area pulls ahead for SaMD and imaging AI.

Salt Lake City is the value play and has been for three years. The cost of living undercuts Boston and Orange County by 30%, the regulatory talent pool is real because of the Edwards and BD presence in the corridor, and Utah candidates accept relocation from Boston, Minneapolis, and the Bay Area at twice the rate that the reverse direction does because the lifestyle math just works for an engineer with kids. We have closed seven Salt Lake searches in the last twelve months. The senior base settles around $122,000 — versus $150,000 for the equivalent seat in Irvine, which is a 19% comp delta that the hiring manager pockets and the candidate trades for a shorter commute and a yard.

If you are budgeting for the senior tier, anchor on the BLS 75th percentile of roughly $138,000, then layer 8% to 14% on top for any of the top five metros above. That is the offer that gets accepted in 14 days. The mid-fives, lower-six budget is the one that sits open for 80 days and then closes 6% higher than the original ceiling because the market moved.

What Pushes the Number Up — And What Does Not

Three things move the offer materially. A cleared regulatory submission as the named technical lead — 510(k), De Novo, or PMA. Active design controls ownership on a current device program. And specialization in one of the three narrow subspecialties where supply is genuinely tight: implantables with biocompatibility, SaMD with IEC 62304, and imaging with DICOM and signal processing depth.

What does not move the offer the way candidates assume: a PhD without industry exposure, a long list of certifications without ownership of a real submission, a masters in BME from a program with no clinical or industry partnership, and generic “biomedical engineering” experience that turns out to be lab automation or non-regulated R&D under a label that the resume parser cannot tell apart from the regulated work that hiring managers are actually paying for.

Equity is real at startups, frequently zero at the big medical device primes. Edwards, Medtronic, and Boston Scientific run cash-heavy comp with modest RSU. A staff engineer offer at one of those will read $165,000 base + $25,000 in RSU. A staff offer at a Series C device startup might read $145,000 base + 0.4% equity that maps to $80,000 expected value at exit on an optimistic comparable. The startup offer requires a four-year vest and the assumption that the comparable holds. Most of our candidates over 35 take the prime offer for a reason.

What Hiring Managers Get Wrong About the Budget

The most common budgeting mistake we see: pricing against ZipRecruiter or PayScale, both of which run 15% to 25% below the actual market for a regulated R&D seat. The req goes up at $95,000. The qualified candidates in that market are at $112,000 to $130,000. The req sits at zero qualified submittals for six weeks. Then the hiring manager calls a recruiter and asks why the role won’t fill. The role will fill. The budget is the problem, and the budget came from a salary aggregator that wasn’t measuring the right population.

Second mistake: assuming “biomedical engineer” is one role. The skills do not transfer cleanly between an implantables R&D engineer and a clinical biomed at a hospital. Different career tracks. Different regulatory exposure. Different comp bands. A req that opens for either is a req that closes for neither.

Third mistake: under-funding the regulatory layer. The senior who can write a verification protocol that survives FDA inspection is a $145,000 engineer, not a $115,000 engineer. The cost of getting that protocol wrong is a Form 483 observation, a six-month delay on the submission, and somewhere between $400,000 and $2 million in burn while the rework happens. The hiring manager who underpaid by $30,000 just blew $1.2 million on the submission delay. We have seen this exact pattern twice in 18 months, both at Series B device startups in the implantables space.

If you are sizing comp against current market and want a sanity check, the KORE1 salary benchmark assistant uses our placed-base data and the BLS anchor to triangulate a range for any role and metro. The aggregator-only number is the wrong starting point. Use it, but only as a floor reference.

Common Questions Hiring Managers Ask About Biomedical Engineer Pay

Do biomedical engineers actually earn more than mechanical or electrical engineers?

Not at the median. BLS puts BME at $106,950, mechanical at $99,510, electrical at $111,860 — and the spread within each is wider than the gap between them. The “BME pays more” narrative is mostly a story about the medical device industry premium, not the BME degree itself. A mechanical engineer at Edwards Lifesciences earns more than a BME at a non-regulated startup. Industry beats degree.

How much does an entry-level biomedical engineer make right out of school?

$68,000 to $85,000 in 2026 for ABET-accredited graduates entering regulated device or biotech R&D. Add about $4,000 to $7,000 for Orange County, San Diego, Boston, or Bay Area cost-of-living premiums. New grads heading into clinical biomed at a hospital come in $10,000 lower — $58,000 to $72,000 in most metros. Master’s at entry adds about $5,000 to $8,000 but the meaningful jump shows up in years three and four when the regulatory exposure starts to compound.

Is a PhD worth it for biomedical engineering salary?

Only for research-track roles and biomaterials. Outside of those, the PhD is roughly neutral on first-job salary and slightly negative on time-to-promotion in most industry tracks because the four-year industry-experience deficit takes longer to close than the PhD premium pays back, and the candidate has spent that same window watching peers ship two devices and own a 510(k) while they finished a dissertation. The exception is academic medicine, government labs, and a handful of imaging algorithms teams at Verily and Google Health where the PhD is effectively a filter for the seat.

What certifications actually move the salary number?

Three. The RAC (Regulatory Affairs Certification) from RAPS adds 8% to 12% on the regulatory and quality track. ASQ Certified Biomedical Auditor matters at the auditor and supplier-quality seat. SAFe or scaled agile certifications matter for SaMD seats where the engineering org is genuinely scaled. The rest of the alphabet soup — six sigma green belts, generic PMP, vendor-specific tooling certs — does not show up in our offers as a comp lift.

How quickly should a biomedical engineer search close?

17 days for a well-scoped mid-level seat at market comp through KORE1’s average for the segment, 28 to 45 days for senior R&D, and 45 to 75 days for staff or principal at a narrow specialization. The cleanest predictor of a long search is not the title — it is whether the req description matches the comp band. Mismatches add weeks.

Is there a shortage of biomedical engineers right now?

There is no shortage at the entry and mid-level. There is a real shortage at the senior-and-up tier inside three specific subspecialties: SaMD with regulatory fluency, implantables with biocompatibility expertise, and imaging signal processing with deep DICOM. The 5% projected BLS growth rate masks a 15%-plus growth rate inside those three pockets where the medical device boom is concentrated and where the actual hiring volume sits at firms like Edwards, Boston Scientific, Medtronic, Stryker, and the second tier of Series C and D device startups that have raised in the last 18 months. Outside those pockets the market is balanced.

How does biomedical engineer pay compare against biotech and life sciences IT roles?

Biomedical engineers and biotech process engineers run within $8,000 of each other at the senior level — both anchored to FDA-regulated industries. Where the comp diverges is at the staff-and-above tier, where biotech process engineering peaks closer to $175,000 and biomedical engineering reaches $190,000 to $210,000 in the device specialty. KORE1 places adjacent roles through our biotech staffing and life sciences IT staffing practices, and the wage data we collect across both confirms the device R&D track edges out biotech-side R&D by about 6%.

If You Are Hiring Biomedical Engineers in 2026

The 2026 budget that closes a senior medical device R&D hire in 14 days is $135,000 to $160,000 base in the top metros, plus a 10% target bonus and a relocation allowance if the candidate is moving from outside the cluster. The 2026 budget that keeps a senior open for 80 days is anything starting with an 11. Do not negotiate against the aggregator floor. Negotiate against the cleared-population reality.

When the search is for a narrow specialization — SaMD, implantables with biocompatibility, imaging signal processing — assume 45 to 75 days even at market-correct comp, because the cleared candidate pool nationally is in the low hundreds and most of those engineers are already inside Edwards, Boston Scientific, Medtronic, or one of the three or four Series D device startups that closed last year. The bar is regulatory ownership of a real device program, not titles on a resume. Talk to a recruiter before the search opens — the cost-of-budget conversation is cheaper than the cost-of-vacancy one.